Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521183 · ClinicalTrials.gov registry record · Phase 1
Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Brian Lally.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00521183: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Brian Lally.
NCT00521183 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Brian Lally. The registered enrollment target is 2 participants, below the 184-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00521183, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Brian Lally.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of cytochlor when given together with tetrahydrouridine and external-beam radiation therapy in treating patients with cancer that has spread to the brain.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Tetrahydrouridine
- DRUG Cytochlor
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT00521183 record still lists
NCT00521183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 184-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT00521183 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00521183 about?
NCT00521183 is a clinical study titled "Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of cytochlor when given together with tetrahydro...
What is the current status of trial NCT00521183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-06. Estimated completion is 2014-05.
What conditions does trial NCT00521183 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00521183?
The interventions under investigation include: Radiation Therapy (RADIATION), Tetrahydrouridine (DRUG), Cytochlor (DRUG).
Who is sponsoring clinical trial NCT00521183?
This trial is sponsored by Brian Lally, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00521183 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00521183's enrollment target sits among peer trials
2 46th of 45 the lowest of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia